Is SGRY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Migration of surgery into the outpatient setting, with revenue (ttm) at ~$3.37 billion (Q2 2026 +2.7% year over year). The bear case rests on leverage is the dominant risk: with reported total debt of ~$4.07 billion and cash of ~$217 million at June 30, 2026 and quarterly interest expense around $69 million, a modest shortfall in adjusted EBITDA moves the equity a great deal more than it moves the enterprise. Analysts covering it are spread from $19.00 to $23.50, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Leverage is the dominant risk: with reported total debt of ~$4.07 billion and cash of ~$217 million at June 30, 2026 and quarterly interest expense around $69 million, a modest shortfall in adjusted EBITDA moves the equity a great deal more than it moves the enterprise. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $19.00, -18.1% from the $23.20 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Migration of surgery into the outpatient setting. Procedures that once required an inpatient stay, particularly total joint replacements, spine and cardiovascular cases, keep moving into ambulatory surgery centers as Medicare adds codes to the covered ASC list and commercial payers steer volume there on cost. The most optimistic analyst target on SGRY is $23.50, +1.3% from the $23.20 price. That figure is only reachable if this thesis works close to its best case.

Leverage is the dominant risk: with reported total debt of ~$4.07 billion and cash of ~$217 million at June 30, 2026 and quarterly interest expense around $69 million, a modest shortfall in adjusted EBITDA moves the equity a great deal more than it moves the enterprise. Reimbursement is the second: Medicare ASC rate updates, Medicaid supplemental and state directed payment programs, and the fate of enhanced Affordable Care Act exchange subsidies all feed directly into payer mix and volume. The gap between adjusted EBITDA and GAAP results is wide, and after the November 2025 guidance cut sent the stock down roughly 25% in a day, several shareholder law firms announced investigations into whether prior margin guidance was supportable, which is a live reputational and disclosure issue rather than an operating one. The joint venture structure means a substantial share of facility cash flow belongs to physician partners, so headline facility growth does not translate one-for-one into value for public shareholders. Roll-up execution risk, elective procedure sensitivity to consumer deductibles, and staffing costs round out the picture. The Idaho Falls sale lowers debt but also removes EBITDA, so leverage improves only modestly, and recent commentary has pointed to softer same-facility volumes, which leaves less margin for error in the November 9, 2026 report. The most pessimistic published target is $19.00, -18.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Surgery Partners operates a network of roughly 180 surgical facilities, mostly ambulatory surgery centers, riding the shift of procedures out of hospitals but carrying meaningful leverage.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Migration of surgery into the outpatient setting) stalling in the reported numbers rather than in the narrative, the risk above (leverage is the dominant risk: with reported total debt of ~$4.07 billion and cash of ~$217 million at June 30, 2026 and quarterly interest expense around $69 million, a modest shortfall in adjusted EBITDA moves the equity a great deal more than it moves the enterprise) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

As of the first quarter of 2026 the company owned or operated about 180 surgical facilities across roughly 30 states, roughly 161 ambulatory surgery centers and about 19 short-stay surgical hospitals, plus anesthesia services and affiliated physician practices. Only about 122 of those facilities are consolidated into the financial statements. The rest are minority stakes, often with buy-up rights that let Surgery Partners take control later.

Not on a GAAP basis at the moment. The company reported a net loss attributable to shareholders of about $77.9 million in 2025 and about $35.9 million in the first quarter of 2026, while adjusted EBITDA was roughly $526 million for 2025 and about $102.3 million in the first quarter. The gap comes mainly from interest expense near $69 million a quarter, heavy depreciation on facilities, and acquisition and transaction costs excluded from the adjusted figure. In the second quarter of 2026 the net loss narrowed to about $15 million on ~$848.9 million of revenue, and trailing net loss was ~$88.6 million.

Reported total debt was ~$4.07 billion at June 30, 2026 against cash of ~$217 million and a market capitalization of ~$1.94 billion in October 2026, so debt holders own most of the enterprise. Net leverage was about 4.3x under the credit agreement in the first quarter of 2026, higher on a strict GAAP calculation. Leverage was 4.4x at the end of the second quarter, before the Idaho Falls proceeds. At that ratio a small miss against the reset adjusted EBITDA target of at least $489 million changes the equity value disproportionately, which is why the shares move violently on guidance changes.